ATA Guidelines Tools

Adults with Differentiated THyroid Cancer - 2025 Update

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/1540959

Contents of this Issue

Navigation

Page 45 of 49

Tables and Figures 46 Figure 8. DATA Framework for Therapy of Radioactive lodine Resistant (RAIR) DTC DATA framework for systemic treatment of patients with RAIR unresectable/metastatic DTC. a Initial staging may involve CT, MRI, and/or PET/CT. Consider brain MRI to rule out brain metastases. b First imaging and Tg monitoring aer 2–6 months; timing thereaer is based on rate of progression and/or development of symptoms. RAIR DTC Assessment for Progression Imaging and biochemical staging a Comprehensive somatic genomic testing Assess progression by serial imaging and Tg b Diagnosis of RAIR DTC YES NO Symptomatic and/or large volume and/or anatomically threatening disease

Articles in this issue

Archives of this issue

view archives of ATA Guidelines Tools - Adults with Differentiated THyroid Cancer - 2025 Update